These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22142375)

  • 21. In vitro metabolic activation of lumiracoxib in rat and human liver preparations.
    Li Y; Slatter JG; Zhang Z; Li Y; Doss GA; Braun MP; Stearns RA; Dean DC; Baillie TA; Tang W
    Drug Metab Dispos; 2008 Feb; 36(2):469-73. PubMed ID: 17998295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerability of lumiracoxib in patients with analgesic intolerance.
    Celikel S; Isik SR; Karakaya G; Kalyoncu AF
    J Investig Allergol Clin Immunol; 2008; 18(4):318-9. PubMed ID: 18714545
    [No Abstract]   [Full Text] [Related]  

  • 23. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
    Hawkey CJ; Ell C; Simon B; Albert J; Keuchel M; McAlindon M; Fortun P; Schumann S; Bolten W; Shonde A; Hugot JL; Yu V; Arulmani U; Krammer G; Rebuli R; Toth E
    Clin Gastroenterol Hepatol; 2008 May; 6(5):536-44. PubMed ID: 18242145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?
    Hinz B; Renner B; Cheremina O; Besz D; Zolk O; Brune K
    Ann Rheum Dis; 2009 Feb; 68(2):289-91. PubMed ID: 19139209
    [No Abstract]   [Full Text] [Related]  

  • 25. No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor.
    Kalbag J; Yeh CM; Milosavljev S; Lasseter K; Oberstein S; Rordorf C
    Pharmacol Res; 2004 Aug; 50(2):181-6. PubMed ID: 15177307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    Hawkey CC; Svoboda P; Fiedorowicz-Fabrycy IF; Nasonov EL; Pikhlak EG; Cousin M; Gitton X; Hoexter G
    J Rheumatol; 2004 Sep; 31(9):1804-10. PubMed ID: 15338504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
    Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.
    Laine L; Goldkind L; Curtis SP; Connors LG; Yanqiong Z; Cannon CP
    Am J Gastroenterol; 2009 Feb; 104(2):356-62. PubMed ID: 19174782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
    Daniels S; Gitton X; Zhou W; Stricker K; Barton S
    J Womens Health (Larchmt); 2008 Apr; 17(3):423-37. PubMed ID: 18373490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty.
    Chan VW; Clark AJ; Davis JC; Wolf RS; Kellstein D; Jayawardene S
    Acta Anaesthesiol Scand; 2005 Nov; 49(10):1491-500. PubMed ID: 16223396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
    Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
    Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Schnitzer TJ; Beier J; Geusens P; Hasler P; Patel SK; Senftleber I; Gitton X; Moore A; Sloan VS; Poór G
    Arthritis Rheum; 2004 Aug; 51(4):549-57. PubMed ID: 15334426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts.
    Kang P; Dalvie D; Smith E; Renner M
    Chem Res Toxicol; 2009 Jan; 22(1):106-17. PubMed ID: 19063590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Australian drugs regulator cancels registration of COX 2 inhibitor.
    Burton B
    BMJ; 2007 Aug; 335(7616):363. PubMed ID: 17717345
    [No Abstract]   [Full Text] [Related]  

  • 36. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
    Willburger RE; Mysler E; Derbot J; Jung T; Thurston H; Kreiss A; Litschig S; Krammer G; Tate GA
    Rheumatology (Oxford); 2007 Jul; 46(7):1126-32. PubMed ID: 17478464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.
    Hawkey CJ; Weinstein WM; Stricker K; Murphy V; Richard D; Krammer G; Rebuli R
    Aliment Pharmacol Ther; 2008 May; 27(9):838-45. PubMed ID: 18221410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diclofenac hepatitis.
    Sallie RW; McKenzie T; Reed WD; Quinlan MF; Shilkin KB
    Aust N Z J Med; 1991 Apr; 21(2):251-5. PubMed ID: 1872757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
    Fricke J; Davis N; Yu V; Krammer G
    J Pain; 2008 Jan; 9(1):20-7. PubMed ID: 17933588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.